Maintain TMO at 80% target weight; two-trigger entry framework with $595 hard stop ahead of Q3 earnings
Hold TMO at 80% target weight with hard stop at $595 (3.6 ATR of room above the Bollinger Band lower boundary at $587). The $595 stop is preferred over $612 to avoid whipsaw given normal volatility around the 50 SMA. Upgrade to Overweight if Q3 shows revenue growth ≥8% with operating margin expanding above 19% (validates operating leverage thesis and confirms forward EPS estimates). Downgrade to Underweight if Q3 prints soft revenue growth (≤5%) or margin compression (confirms bear pricing-pressure/mix-shift thesis and triggers multiple compression). The 18.2% operating margin flatness despite 5x revenue acceleration is the single most important variable to watch at Q3.
| Position | Action |
|---|---|
| Default position sizing | Maintain at 80% of target core weight |
TMO's reacceleration to +10.5% YoY revenue growth, 23.7x forward P/E on ~48% EPS growth, fortress balance sheet with $6.3B FCF and $9.85B cash, and status as the scale leader in life sciences makes the October pullback a gift rather than a warning.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 663.24 | bearish |
| close_50_sma | 615.46 | bullish |
| close_200_sma | 541.34 | bullish |
| macd | 18.34 | bearish |
| macdh | -0.12 | bearish |
| rsi | 55.68 | neutral |
| boll_ub | 701.42 | neutral |
| boll_lb | 587.14 | neutral |
| vwma | 657.64 | bearish |
| atr | 15.91 | neutral |
Support: 541.34 · 587.14 · 615.46 · 644.28 | Resistance: 679.61 · 682.98 · 701.42
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
TMO's forward P/E of 23.7x is massively underappreciated given ~48% expected EPS growth and the stock's quality profile
↩ rebuts: “The trailing P/E is 35x — too expensive”
EV: +5.7% · concedes: FX headwinds from ~40% non-USD revenue are a real but manageable headwind; Goodwill is $65B with associated tail impairment risk; MACD histogram turned negative (-0.12), though described as noise rather than confirmed momentum collapse; Short-term trend broken (price below 10 EMA); Olink integration still has 2-3 quarters before full acceleration is visible
TMO is a high-quality compounder but is mispriced at 23.7x forward P/E given aggressive analyst estimates (48% EPS growth target), absent margin expansion, bearish technical signals after a 5-week rally, and a macro environment that historically compresses premium multiples; patience is the alpha as the path of least resistance on a break below $615 is to $587, then $541.
EV: -$160/share on TTM earnings multiple compression; -$130/share on forward earnings compression; target downside to $587 then $541 on technical failure · concedes: TMO is a high-quality compounder with a real moat; Q2'26 top-line acceleration was real (10.5% YoY growth); TMO is defensive in a recession scenario; The moat will survive this drawdown — don't sell the whole position
→ vs conservative: Waiting for 50 SMA retest at 615.46 risks missing the move; the retest may never come as the 50 SMA is rising and the catalyst path to 700-plus is clear
→ vs conservative: Goodwill-to-book ratio at 93% is textbook for acquisition-driven life sciences rollups; intangible-heavy balance sheets are the industry rule, not an exception
→ vs conservative: Flat 18.2% operating margin during 10.5% revenue acceleration demonstrates operating leverage gains, not deterioration
→ vs conservative: 48% forward EPS growth estimates are aggressive but justified by actual Q2 beat, biopharma R&D inflection, and Olink ramp
→ vs neutral: Macro hawkishness favors quality compounders with cash flow and rising earnings; TMO's defensive nature with 0.85 beta and 6.3B FCF is exactly the right asset in this environment
→ vs neutral: Quiet sentiment signals institutional accumulation before retail attention, not lack of conviction
→ vs conservative: Overweighting short-term MACD noise (minus 0.12 histogram) while underweighting structural EPS reacceleration
TMO exhibits a mixed technical picture: the long-term and medium-term trends remain bullish with price trading +20.5% above the 200 SMA and +6.0% above the 50 SMA, but short-term momentum has shifted bearish following the Oct 1 close below the 10 EMA (663.24) and a fresh MACD bearish crossover. RSI has cooled to neutral (55.68) from likely overbought levels, and Bollinger Bands show elevated volatility with the upper band at 701.42 and lower band at 587.14. The critical fulcrum is the 50 SMA at 615.46—if it holds, the selloff is a healthy pullback within an intact uptrend; a break below opens downside targets toward 587 (BB lower) and 541 (200 SMA). The recommendation is HOLD with a bullish bias but defensive posture, with stops placed near 612 (just below the 50 SMA).
Market Cap
$241.26 B
P/E (TTM)
35.16x
Forward P/E
23.69x
PEG Ratio
2.01
Price / Book
4.58x
EV/EBITDA (approx)
~23.2x
52-Week High
$683.63
52-Week Low
$435.27
50-Day MA
$613.28
200-Day MA
$541.81
Beta
0.854
Dividend Yield
0.28%
Book Value / Share
$142.47
EPS (TTM)
$18.56
Forward EPS
$27.55
Revenue 2025
$44.56 B
Revenue Q2 2026
$11.99 B (+10.5% YoY)
Revenue YoY Growth 2025
+3.9%
Net Income 2025
$6.70 B
Diluted EPS 2025
$17.74
Gross Margin 2025
40.9%
Operating Margin 2025
18.2%
Net Margin TTM
15.0%
ROE
13.5%
ROA
5.1%
FCF Margin 2025
14.1%
Total Assets
$110.34 B
Total Debt
$39.39 B
Net Debt
$29.53 B
Net Debt / EBITDA
~2.5x
Current Ratio
1.55x
Stockholders' Equity
$53.41 B
Goodwill + Intangibles
$65.2 B
OCF 2025
$7.82 B
FCF 2025
$6.29 B
CapEx 2025
$1.53 B
FCF / Net Income
94%
Annual Buybacks
$3.0 B
Annual Dividends
$0.64 B
Annual M&A Spend
$4.0 B
Strengths
Concerns
Thermo Fisher Scientific is a blue-chip life sciences tools conglomerate with a history of value-creating M&A (Thermo Electron + Fisher Scientific 2006, PPD 2021, Olink 2023). After a soft 2023-2024 post-COVID normalization period, the company is now experiencing a revenue inflection with Q2 2026 growth of +10.5% YoY, supported by biopharma R&D recovery and Olink ramp. The forward P/E of 23.69x is reasonable given expected EPS growth to $27.55 (~48% YoY), and the 2.5x Net Debt/EBITDA capital structure is investment-grade. Capital allocation is disciplined with ~$3B/yr in buybacks, $600M in dividends, and $3-4B in bolt-on M&A, all funded by consistent ~$6.3B annual free cash flow. The primary risk is valuation, as the trailing P/E of 35.16x near 52-week highs provides limited margin of safety; the report recommends a HOLD for current holders and a scaled-in BUY on pullbacks to the 50-DMA (~$613) or 200-DMA (~$542).
Macro: Hawkish Fed backdrop with 97% probability of zero rate cuts in 2026 ($8.7M Polymarket volume) and 74% probability of FOMC hold at October 2026 meeting ($11.8M Polymarket volume), though this represents a -41pp shift toward hold vs. hike from prior week. The 10-year Treasury yield touched its highest level since 2002 with the biggest monthly gain since 2022 for September, though yields eased Thursday 2026-10-01 alongside an equity rally. US recession probability is 8% (down -2pp WoW) with globally low recession risk. FRED macro prints (CPI, Core PCE, unemployment, fed funds, 10Y, yield curve) were unavailable due to API configuration. Sector rotation favored AI/services names (IBM +5%, Accenture +20–23%, Infosys +8%) over healthcare/life sciences.